The 36-month beta value for WVE is at -0.84. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for WVE is 122.54M, and currently, shorts hold a 8.11% of that float. The average trading volume for WVE on April 10, 2025 was 1.17M shares.
WVE) stock’s latest price update
The stock price of Wave Life Sciences Ltd (NASDAQ: WVE) has dropped by -11.24 compared to previous close of 6.14. Despite this, the company has seen a fall of -17.92% in its stock price over the last five trading days. zacks.com reported 2025-03-28 that Investors interested in the Genomics and Synthetic Biology theme should consider these stocks: Twist Bioscience Corporation, Wave Life Sciences, and CRISPR Therapeutics AG.
WVE’s Market Performance
Wave Life Sciences Ltd (WVE) has seen a -17.92% fall in stock performance for the week, with a -49.58% decline in the past month and a -56.40% plunge in the past quarter. The volatility ratio for the week is 14.61%, and the volatility levels for the past 30 days are at 8.69% for WVE. The simple moving average for the past 20 days is -34.21% for WVE’s stock, with a -44.48% simple moving average for the past 200 days.
Analysts’ Opinion of WVE
Many brokerage firms have already submitted their reports for WVE stocks, with Wedbush repeating the rating for WVE by listing it as a “Outperform.” The predicted price for WVE in the upcoming period, according to Wedbush is $18 based on the research report published on April 08, 2025 of the current year 2025.
Jefferies, on the other hand, stated in their research note that they expect to see WVE reach a price target of $26. The rating they have provided for WVE stocks is “Buy” according to the report published on February 25th, 2025.
Raymond James gave a rating of “Strong Buy” to WVE, setting the target price at $22 in the report published on October 16th of the previous year.
WVE Trading at -44.52% from the 50-Day Moving Average
After a stumble in the market that brought WVE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.43% of loss for the given period.
Volatility was left at 8.69%, however, over the last 30 days, the volatility rate increased by 14.61%, as shares sank -45.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.40% lower at present.
During the last 5 trading sessions, WVE fell by -16.42%, which changed the moving average for the period of 200-days by +6.53% in comparison to the 20-day moving average, which settled at $8.29. In addition, Wave Life Sciences Ltd saw -55.94% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WVE starting from HENRY CHRISTIAN O, who sale 10,500 shares at the price of $9.77 back on Mar 20 ’25. After this action, HENRY CHRISTIAN O now owns 16,115 shares of Wave Life Sciences Ltd, valued at $102,574 using the latest closing price.
Christian Henry, the Director of Wave Life Sciences Ltd, proposed sale 10,500 shares at $9.77 during a trade that took place back on Mar 20 ’25, which means that Christian Henry is holding shares at $102,579 based on the most recent closing price.
Stock Fundamentals for WVE
Current profitability levels for the company are sitting at:
- -1.02 for the present operating margin
- 0.61 for the gross margin
The net margin for Wave Life Sciences Ltd stands at -0.9. The total capital return value is set at -0.46. Equity return is now at value -73.24, with -30.94 for asset returns.
Based on Wave Life Sciences Ltd (WVE), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -5.94.
Currently, EBITDA for the company is -110.4 million with net debt to EBITDA at 2.72. When we switch over and look at the enterprise to sales, we see a ratio of 5.08. The receivables turnover for the company is 76.16for trailing twelve months and the total asset turnover is 0.31. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.89.
Conclusion
In conclusion, Wave Life Sciences Ltd (WVE) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
